SLC5A2 and liver dysplastic nodule: Taking a step forward, An et al. developed another animal model—a rhesus macaque model of DN—and the MSCs administered in the study ameliorated the early stage of DN potentially by adjusting sodium-glucose cotransporter 2 (SGLT2) expression and resulted in improved glycemic control and anti-inflammation [69].